# Lonza AG - Inspection Records Source: https://www.globalkeysolutions.net/companies/lonza-ag/7084f7e6-ce36-429f-942a-28e759416e70 > Inspection records and compliance data for Lonza AG in Visp, None. Access full analysis and detailed observations. --- ## Details - Name: Lonza AG - FEI Number: 3002930340 - City: Visp - State: None - Country Name: Switzerland - Address Line 1: Lonzastrasse 2 - Zip Code: None - Business Operations: API MANUFACTURE, API/FDF ANALYTICAL TESTING ## Related Documents - [483 - Lonza AG - 2025-10-28](https://www.globalkeysolutions.net/records/483/lonza-ag/65951ebb-e28b-4ed1-9e9b-61dbae635dd6) — source: FDA, date: October 28, 2025 - [FDA Inspection 1303682 - Lonza AG - 2025-10-28](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/78fcfce7-3d24-4ce5-9b7b-b09a46e71fee) — source: FDA, date: October 28, 2025 - [FDA Inspection 1279014 - Lonza AG - 2025-04-04](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/c8382a61-bc25-45cc-bf72-f8219f1cd14b) — source: FDA, date: April 4, 2025 - [483 - Lonza AG - 2023-03-28](https://www.globalkeysolutions.net/records/483/lonza-ag/f928f76e-a480-4048-ae0c-9c4dc56c8947) — source: FDA, date: March 28, 2023 - [EIR - Lonza AG - 2023-03-28](https://www.globalkeysolutions.net/records/eir/lonza-ag/6ebda501-7241-4d95-8fe7-a77f9ba19386) — source: FDA, date: March 28, 2023 - [483 - Lonza AG - 2023-03-28](https://www.globalkeysolutions.net/records/483/lonza-ag/8b543d73-8cd2-405b-8095-49e641ba5fb2) — source: FDA, date: March 28, 2023 - [FDA Inspection 1204183 - Lonza AG - 2023-03-28](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/87c8c9aa-762b-4daa-a90c-57b1f749b6c0) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 28, 2023 - [483 - Lonza AG - 2019-03-29](https://www.globalkeysolutions.net/records/483/lonza-ag/d2b94531-82a9-47ee-8dfc-06a69d21c1c6) — source: FDA, date: March 29, 2019 - [483 - Lonza AG - 2017-12-15](https://www.globalkeysolutions.net/records/483/lonza-ag/8a04ca07-4b1d-4652-b808-fa39c435dba7) — source: FDA, date: December 15, 2017 - [FDA Inspection 1035618 - Lonza AG - 2017-12-15](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/6aabdbe9-cb78-4447-878b-509514b56a44) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 15, 2017 - [FDA Inspection 967811 - Lonza AG - 2016-03-11](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/d3cf442a-abb3-4302-8fda-dc73abdabba3) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 11, 2016 - [FDA Inspection 893677 - Lonza AG - 2014-08-29](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/f16885c5-b179-45f7-b826-f1969e2e6fa9) — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 29, 2014 - [FDA Inspection 877791 - Lonza AG - 2014-04-02](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/91715345-5bf7-4e52-ab96-660ea026d8e4) — classification: No Action Indicated (NAI), source: FDA, date: April 2, 2014 - [FDA Inspection 877791 - Lonza AG - 2014-04-02](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/0b34a418-99bd-43d6-aff6-9dc35a24a434) — classification: No Action Indicated (NAI), source: FDA, date: April 2, 2014 - [FDA Inspection 826508 - Lonza AG - 2013-04-12](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/e7f7ad5d-231a-4966-8821-f6d489c27d3c) — classification: No Action Indicated (NAI), source: FDA, date: April 12, 2013 - [FDA Inspection 818560 - Lonza AG - 2012-09-18](https://www.globalkeysolutions.net/records/fda_inspections/lonza-ag/0bbb540e-edb5-4c8d-ae18-5c3d4de9a3cb) — classification: No Action Indicated (NAI), source: FDA, date: September 18, 2012 ## Related Companies - [Shilpa Pharma Lifesciences Limited](https://www.globalkeysolutions.net/companies/shilpa-pharma-lifesciences-limited/4f617c67-eea7-483d-b9c7-b1dd31aabcff) - [Bachem Americas, Inc.](https://www.globalkeysolutions.net/companies/bachem-americas-inc/f0157d2d-6b0c-4b13-afd4-551c2ab94aad) - [Solara Active Pharma Sciences Limited](https://www.globalkeysolutions.net/companies/solara-active-pharma-sciences-limited/8f3f8236-f49d-43e3-84af-2cb404fb8264) - [Apitoria Pharma Private Limited](https://www.globalkeysolutions.net/companies/apitoria-pharma-private-limited/c56154eb-1a77-4f64-9db0-4ae380d6b65e) - [UBE Corporation](https://www.globalkeysolutions.net/companies/ube-corporation/76ca3dd5-0b44-4d3d-af9f-062d88ca7b3a) - [Takeda Manufacturing Singapore Pte. Ltd.](https://www.globalkeysolutions.net/companies/takeda-manufacturing-singapore-pte-ltd/4ae048ca-a89e-47c7-b5a2-60d372157742) - [Novacyl Roussillon](https://www.globalkeysolutions.net/companies/novacyl-roussillon/5a1bc6b5-5b17-4058-9698-82735b553d87) - [Protein Sciences Corporation](https://www.globalkeysolutions.net/companies/protein-sciences-corporation/5a8e39ec-a92e-42d6-a577-365d1d089624) - [Chinese Peptide Company](https://www.globalkeysolutions.net/companies/chinese-peptide-company/ba8c6a32-f679-405b-bb0a-e82713b7cb62) - [Cytovance Biologics Inc.](https://www.globalkeysolutions.net/companies/cytovance-biologics-inc/a03c370a-5e60-4617-95b1-521a1d305ac2) ## Related Officers - [Tiara N Brown-Crosen](https://www.globalkeysolutions.net/people/tiara-n-brown-crosen/8255649d-25a9-49fa-a28d-0cdda922c0c3) - [Frances Namuswe](https://www.globalkeysolutions.net/people/frances-namuswe/d64cc7a2-3840-41c9-ae6c-fe225a651369) - [Ralph M. Bernstein](https://www.globalkeysolutions.net/people/ralph-m-bernstein/72173dfb-24ae-42a1-af9e-1dc7da02ed87) - [Reyes Candau-Chacón, Ph.D.](https://www.globalkeysolutions.net/people/reyes-candau-chacon-phd/c4e9fd50-2a2b-41a7-9cd0-db29dbb9171a) - [Santos E. Camara](https://www.globalkeysolutions.net/people/santos-e-camara/18cea942-f6f9-4dec-9ce9-1c01c39009ce) - [Vaishali J. Patel](https://www.globalkeysolutions.net/people/vaishali-j-patel/3d515b84-e0fd-4f96-914c-f7f09e2de307)